

Ana Almeida

Discloser Identifier: 992624

Disclosure Purpose: 22-09760

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Early Pegylated Interferon Lambda Treatment for COVID-19

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Paul Arora

Discloser Identifier: 1086823

Disclosure Purpose: 22-09760

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Cytel	Employment	Self
<i>Title:</i> Vice President, Advanced Epidemiology <i>Additional Information:</i>		<i>Position Description:</i> Employee

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Early Treatment with Pegylated Interferon Lambda among COVID-19 Patients

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Mia Biondi

Discloser Identifier: 1086821

Disclosure Purpose: 22-09760

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

EFFECT OF EARLY TREATMENT WITH PEGYLATED INTERFERON LAMBDA AMONG PATIENTS WITH COVID-19

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Carina Bitaraes

Discloser Identifier: 1086937

Disclosure Purpose: 22-09760

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Early Pegylated Interferon Lambda Treatment for COVID-19

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Eduardo Callegari

Discloser Identifier: 1047212

Disclosure Purpose: 22-09760

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Early Pegylated Interferon Lambda Treatment for COVID-19

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Vitoria Campos

Discloser Identifier: 1047210

Disclosure Purpose: 22-09760

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Early Pegylated Inteferon Lambda Treatment for COVID-19

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Ingrid Choong

Discloser Identifier: 979089

Disclosure Purpose: 22-09760

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Early Treatment with Pegylated Interferon Lambda Among COVID-19 Patients

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Jordan Feld

Discloser Identifier: 565518

Disclosure Purpose: 22-09760

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Eiger Biopharmaceuticals	Grant / Contract	Other - Institution
<i>Recipient Name:</i> University Health Network <i>Grant / Contract Description:</i> Peginterferon lambda for COVID-19: medication (Phase II), funding (Phase III) <i>Additional Information:</i>		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
Gilead Sciences	Grant / Contract	Other - Institution
<i>Recipient Name:</i> University Health Network <i>Grant / Contract Description:</i> Evaluation of tenofovir to prevent HBV reactivation, Evaluation of HCV treatment in psychiatric care <i>Additional Information:</i>		
<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
Pardes Biosciences	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i>		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

EFFECT OF EARLY TREATMENT WITH PEGYLATED INTERFERON LAMBDA AMONG PATIENTS WITH COVID-19

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

thaigo ferreira

Discloser Identifier: 1047209

Disclosure Purpose: 22-09760

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Early Treatment with Pegylated Interferon Lambda among COVID-19 Patients

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Adhemar Figueiredo Neto

Discloser Identifier: 992625

Disclosure Purpose: 22-09760

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Early Pegylated Interferon Lambda Treatment for COVID-19.

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

James Forrest

Discloser Identifier: 992607

Disclosure Purpose: 22-09760

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Early Pegylated Interferon Lambda Treatment for COVID-19

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Adelino Freire

Discloser Identifier: 1107645

Disclosure Purpose: 22-09760

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Early Treatment with Pegylated Interferon Lambda among COVID-19 Patients

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Jeffrey Glenn

Discloser Identifier: 350747

Disclosure Purpose: 22-09760

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Eiger BioPharmaceuticals	Fiduciary Officer	Self
<i>Official Title:</i> Director <i>Additional Information:</i>		<i>Position Description:</i> Founder; Board of Directors
Eiger BioPharmaceuticals	Stock	Self
<i>Additional Information:</i>		
Eiger BioPharmaceuticals	Stock Option	Self
Additional Information:		
Eiger Group International, Inc.	Fiduciary Officer	Self
<i>Official Title:</i> President <i>Additional Information:</i>		<i>Position Description:</i>
Eiger Group International, Inc.	Stock	Self
<i>Additional Information:</i>		

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

EFFECT OF EARLY TREATMENT WITH PEGYLATED INTERFERON LAMBDA AMONG PATIENTS WITH COVID-19

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Christina Guo

Discloser Identifier: 1070109

Disclosure Purpose: 22-09760

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Early Treatment with Pegylated Interferon Lambda among COVID-19 Patients

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Gordon Guyatt

Discloser Identifier: 332056

Disclosure Purpose: 22-09760

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Early Pegylated Interferon Lambda Treatment for COVID-19

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Bettina Hansen

Discloser Identifier: 874067

Disclosure Purpose: 22-09760

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Eiger BioPharmaceuticals	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Biostatistical advice in design and analysis of studies <i>Additional Information:</i>		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Early Treatment with Pegylated Interferon Lambda among COVID-19 Patients

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Ofir Harari

Discloser Identifier: 992608

Disclosure Purpose: 22-09760

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Early Treatment with Pegylated Interferon Lambda among COVID-19 Patients

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Colin Hislop

Discloser Identifier: 979088

Disclosure Purpose: 22-09760

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

EARLY TREATMENT WITH PEGYLATED INTERFERON LAMBDA AMONG PATIENTS WITH COVID-19

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Christopher Kandel

Discloser Identifier: 400288

Disclosure Purpose: 22-09760

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Early Treatment with Pegylated Interferon Lambda among COVID-19 Patients

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Steve Kanters

Discloser Identifier: 1086820

Disclosure Purpose: 22-09760

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
RainCity Analytics	Employment	Self
<i>Title:</i> Director <i>Additional Information:</i>		<i>Position Description:</i>

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

EARLY PEGYLATED INTERFERON LAMBDA TREATMENT FOR COVID-19

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Robert Kozak

Discloser Identifier: 983756

Disclosure Purpose: 22-09760

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Early Treatment with Pegylated interferon lambda among COVID-19 patients

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 1086819

Disclosure Purpose: 22-09760

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Raincity analytics	Employment	Self
<i>Title:</i> Associate Director <i>Additional Information:</i>		<i>Position Description:</i>

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Early Pegylated Interferon Lambda Treatment for COVID-19

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Paula McKay

Discloser Identifier: 674367

Disclosure Purpose: 22-09760

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Early Treatment with Pegylated Interferon Lambda among COVID-19 Patients

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Aline Milagres

Discloser Identifier: 992627

Disclosure Purpose: 22-09760

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Early Pegylated Interferon Lambda Treatment for COVID-19

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 930612

Disclosure Purpose: 22-09760

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

EFFECT OF EARLY TREATMENT WITH PEGYLATED INTERFERON LAMBDA AMONG PATIENTS WITH COVID-19

3. **Are you the corresponding author?**

Yes.

- a. **Please list the other authors' names here.**

Gilmar Reis, MD, PhD;1,2,3,4 Eduardo Augusto dos Santos Moreira Silva, MD, PhD;2,3 Daniela Carla Medeiros Silva, MD, PhD;2,3 Lehana Thabane, PhD;4 Vitoria Helena de Souza Campos;2,3 Thiago Santiago Ferreira, MD;2 Castilho Vitor Quirino dos Santos;2,3 Ana Maria Ribeiro Nogueira, MD;6 Ana Paula Figueiredo Guimaraes Almeida, MD;7 Leonardo Cançado Monteiro Savassi, MD, PhD;5 Adhemar Dias de Figueiredo Neto MD, PhD;8 Ana Carolina Fialho Dias Rocha, PhD;2 Carina Bitarães, RN;5,6 Aline Cruz Milagres, RN;5,6 Eduardo Diniz Callegari, MD;7 Maria Izabel Campos Simplicio, BScPharm;2 Luciene Barra Ribeiro, RN, MPH;2 Rosemary Oliveira;2 Ofir Harari, PhD;10 Lindsay A Wilson, MSc;1 Jamie I. Forrest, PhD, MPH;11 Hinda Ruton, MSc;10 Sheila Sprague, PhD;4 Paula McKay, MSc;4 Christina M. Guo, BCom;11 Eve Limbrick-Oldfield, PhD;12 Steve Kanters, PhD;12 Gordon H. Guyatt, MD;4 Craig R. Rayner, PharmD, FRCP Edin;13, 14 Christopher Kandel MD;15 Mia J. Biondi PhD;16 Robert Kozak PhD;17 Bettina Hansen PhD;9,18 M. Atif Zahoor PhD;19 Paul Arora, PhD;10 Colin Hislop, M.B.B.S;19 Ingrid Choong, PhD;19 Jordan J. Feld, MD, MPH;20 Jeffrey S. Glenn, MD, PhD

Certification

I certify that the information provided in this disclosure is complete and accurate.

Ana Maria Nogueira

Discloser Identifier: 1047211

Disclosure Purpose: 22-09760

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Early Pegylated Interferon Lambda Treatment for COVID-19

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Rosemary Oliveira

Discloser Identifier: 992632

Disclosure Purpose: 22-09760

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Early Treatment with Pegylated Interferon Lambda among COVID-19 patients

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 1047216

Disclosure Purpose: 22-09760

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
AstraZeneca	Grant / Contract	Other - Certara
<p><i>Recipient Name:</i> Certara <i>Grant / Contract Description:</i> Provision of clinical pharmacology and drug development advice <i>Additional Information:</i> I am an employee of Certara</p> <p><i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research</p>		
Bill and Melinda Gates Foundation	Grant / Contract	Other - Certara
<p><i>Recipient Name:</i> Certara <i>Grant / Contract Description:</i> Certara has received financial support to provide scientific input into various COVID activities <i>Additional Information:</i> I am an employee of Certara which is a consulting organization in medicine development.</p> <p><i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research</p>		
Certara	Employment	Self
<p><i>Title:</i> Certara Distinguished Scientist <i>Additional Information:</i> I am employed by Certara</p> <p><i>Position Description:</i> Various positions over tenure, main role is provide drug development advice to clients as consultant.</p>		
Certara	Stock	Self
<i>Additional Information:</i>		
CSIRO	Grant / Contract	Other - Certara
<p><i>Recipient Name:</i> Certara <i>Grant / Contract Description:</i> Provision of drug development advice and strategic advice on pandemic preparedness <i>Additional Information:</i> I am an employee of Certara</p> <p><i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research</p>		
Daichi Sankyo	Grant / Contract	Other - Certara
<p><i>Recipient Name:</i> Certara <i>Grant / Contract Description:</i> Provision of quantitative pharmacology and drug development advice <i>Additional Information:</i> I am an employee of Certara</p> <p><i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research</p>		
Department of Health	Grant / Contract	Other - Certara
<p><i>Recipient Name:</i> Certara <i>Grant / Contract Description:</i> Australian gov department of health for advice on putative COVID therapeutics <i>Additional Information:</i></p> <p><i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Other - Advice on putative therapeutics</p>		
medicines development for global health	Grant / Contract	Other - Certara

Entity	Type	Interest Held By
<i>Recipient Name:</i> Certara <i>Grant / Contract Description:</i> Clinical pharmacology and drug development advice <i>Additional Information:</i> I am an employee of Certara that regularly consults to Medicines Development for Global Health <i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
Merck	Grant / Contract	Other - Certara
<i>Recipient Name:</i> Certara <i>Grant / Contract Description:</i> Provision of clinical pharmacology and drug development advice <i>Additional Information:</i> I am an employee of Certara <i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
novaquest	Grant / Contract	Other - Certara
<i>Recipient Name:</i> Certara <i>Grant / Contract Description:</i> Drug development due diligence advice <i>Additional Information:</i> I am an employee of Certara <i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
Pfizer	Grant / Contract	Other - Certara
<i>Recipient Name:</i> Certara <i>Grant / Contract Description:</i> Provision of clinical pharmacology and drug development advice <i>Additional Information:</i> I am an employee of Certara <i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
Regeneron Pharmaceuticals	Grant / Contract	Other - Certara
<i>Recipient Name:</i> Certara <i>Grant / Contract Description:</i> Provision of clinical pharmacology and drug development advice <i>Additional Information:</i> I am an employee of Certara <i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

Yes.

- a. **Please describe those relationships.**

I am an employee of Certara. Certara is an organization that broadly consults to pharmaceutical, government and NGOs. With an abundance of caution and transparency I have included such examples in the disclosure.

2. **What is the manuscript title?**

Early Treatment with Pegylated Interferon Lambda among COVID-19 Patients

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Gilmar Reis

Discloser Identifier: 992600

Disclosure Purpose: 22-09760

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Early Pegylated Interferon Lambda Treatment for COVID-19

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Luciene Ribeiro

Discloser Identifier: 992631

Disclosure Purpose: 22-09760

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Early Pegylated interferon lambda treatment for covid-19

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Ana Carolina Rocha

Discloser Identifier: 1086935

Disclosure Purpose: 22-09760

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Early Pegylated Interferon Lambda Treatment for COVID-19

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Hinda Ruton

Discloser Identifier: 1047213

Disclosure Purpose: 22-09760

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Early Treatment with Pegylated Interferon Lambda among COVID-19 Patients

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Castilho Santos

Discloser Identifier: 992623

Disclosure Purpose: 22-09760

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Early Pegylated Interferon Lambda Treatment for COVID-19

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Leonardo Savassi

Discloser Identifier: 992626

Disclosure Purpose: 22-09760

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Early Pegylated Interferon Lambda Treatment for COVID-19

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Daniela Carla Silva

Discloser Identifier: 992603

Disclosure Purpose: 22-09760

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Early Pegylated Interferon Lambda Treatment for COVID-19

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

EDUARDO AUGUSTO DOS SANTOS SILVA

Discloser Identifier: 992601

Disclosure Purpose: 22-09760

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Early Pegylated Interferon Lambda Treatment for COVID-19

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Maria Izabel Simplicio

Discloser Identifier: 992630

Disclosure Purpose: 22-09760

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Early Pegylated Interferon Lambda Treatment for COVID-19

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Sheila Sprague

Discloser Identifier: 620661

Disclosure Purpose: 22-09760

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Early Treatment with Pegylated Interferon Lambda among COVID-19 Patients

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Lehana Thabane

Discloser Identifier: 415383

Disclosure Purpose: 22-09760

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

EFFECT OF EARLY TREATMENT WITH PEGYLATED INTERFERON LAMBDA AMONG PATIENTS WITH COVID-1

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Lindsay Wilson

Discloser Identifier: 1091283

Disclosure Purpose: 22-09760

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

EFFECT OF EARLY TREATMENT WITH PEGYLATED INTERFERON LAMBDA AMONG PATIENTS WITH COVID-19

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Muhammad Atif Zahoor

Discloser Identifier: 874064

Disclosure Purpose: 22-09760

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Early Pegylated Interferon Lambda Treatment for COVID-19

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.